Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H24N2O4S |
| Molecular Weight | 388.481 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)S(=O)(=O)N2CCC[C@H]2C(=O)NC3=CC(C)=CC(C)=C3
InChI
InChIKey=NHPQGZOBHSVTAQ-IBGZPJMESA-N
InChI=1S/C20H24N2O4S/c1-14-11-15(2)13-16(12-14)21-20(23)19-5-4-10-22(19)27(24,25)18-8-6-17(26-3)7-9-18/h6-9,11-13,19H,4-5,10H2,1-3H3,(H,21,23)/t19-/m0/s1
| Molecular Formula | C20H24N2O4S |
| Molecular Weight | 388.481 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
ACT-462206 is a new, potent, and selective dual orexin receptor antagonist that inhibits the stimulating effects of the orexin peptides at both the orexin 1 and 2 receptors. ACT-462206 shows anxiolytic-like properties in rodents without affecting cognition and motor function. It is therefore a potential candidate for the treatment of insomnia and was in phase I of clinical trial, but this research has been discontinued.
CNS Activity
Originator
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
891 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24691844 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACT-462206 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27975 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24691844 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACT-462206 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
11.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24691844 |
1500 mg single, oral dose: 1500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACT-462206 plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:52:48 GMT 2023
by
admin
on
Sat Dec 16 11:52:48 GMT 2023
|
| Record UNII |
64ONO62P28
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
40924317
Created by
admin on Sat Dec 16 11:52:48 GMT 2023 , Edited by admin on Sat Dec 16 11:52:48 GMT 2023
|
PRIMARY | |||
|
ACT-462206
Created by
admin on Sat Dec 16 11:52:48 GMT 2023 , Edited by admin on Sat Dec 16 11:52:48 GMT 2023
|
PRIMARY | Tocris Cat. No. 5319: ACT 462206Biological Activity: Potent, dual orexin receptor antagonist (IC50 values are 11 and 60 nM for OX2 and OX1 receptors respectively). Exhibits anxiolytic-like properties in vivo. Brain penetrant. | ||
|
1361321-96-1
Created by
admin on Sat Dec 16 11:52:48 GMT 2023 , Edited by admin on Sat Dec 16 11:52:48 GMT 2023
|
PRIMARY | |||
|
64ONO62P28
Created by
admin on Sat Dec 16 11:52:48 GMT 2023 , Edited by admin on Sat Dec 16 11:52:48 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
INHIBITOR
IC50
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Originator: Actelion Pharmaceuticals; Mechanism of Action: Orexin receptor type 1 antagonist, Orexin receptor type 2 antagonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Discontinued for Insomnia; Most Recent Events: 19 Jul 2012 Discontinued - Phase-I for Insomnia (in volunteers) in Switzerland (PO), 31 Jan 2012 Actelion Pharmaceuticals completes a phase I trial in Insomnia (in volunteers) in Netherlands (NCT01954589), 30 Nov 2011 Phase-I clinical trials in Insomnia (in volunteers) in Netherlands (PO)
|
||
|
ACTIVE MOIETY |
ACT-462206 was generally well tolerated. Sleepiness, headache, and fatigue were the most frequently reported adverse events. The incidence of sleepiness appeared dose-dependent. ACT-462206 was absorbed with a median tmax of 1.5-4.0 hours. The elimination half-life varied from 4.8 to 11.2 hours. A clinically relevant reduction in vigilance and attention, alertness, and motor coordination was recorded at ACT-462206 doses 200mg. The onset was between 20 and 45 minutes after drug intake, the maximum effect between 1 and 2 hours after drug administration, and these impairing effects largely disappeared within 8hours post-dose. Doses of 400-1,000mg ACT-462206 were similarly efficacious to 400mg almorexant, with a trend for an earlier onset of action with ACT-462206. The present results confirm the activity of ACT-462206 as an orexin antagonist.
|
||
|
ACTIVE MOIETY |
Official Title: Double-blind, Placebo- and Active-controlled, Randomized, Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206 in Healthy Male Subjects
Purpose: A study of ACT-462206 to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamic of ascending single doses of ACT-462206, a novel dual orexin receptor antagonist in healthy male subjects.
|
